JP2021521796A5 - - Google Patents

Info

Publication number
JP2021521796A5
JP2021521796A5 JP2020557924A JP2020557924A JP2021521796A5 JP 2021521796 A5 JP2021521796 A5 JP 2021521796A5 JP 2020557924 A JP2020557924 A JP 2020557924A JP 2020557924 A JP2020557924 A JP 2020557924A JP 2021521796 A5 JP2021521796 A5 JP 2021521796A5
Authority
JP
Japan
Prior art keywords
oligonucleotide according
nucleotides
oligonucleotide
antisense
sequence
Prior art date
Application number
JP2020557924A
Other languages
English (en)
Japanese (ja)
Other versions
JP7357002B2 (ja
JPWO2019204021A5 (https=
JP2021521796A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/025253 external-priority patent/WO2019204021A1/en
Publication of JP2021521796A publication Critical patent/JP2021521796A/ja
Publication of JPWO2019204021A5 publication Critical patent/JPWO2019204021A5/ja
Publication of JP2021521796A5 publication Critical patent/JP2021521796A5/ja
Priority to JP2023159941A priority Critical patent/JP2023174697A/ja
Application granted granted Critical
Publication of JP7357002B2 publication Critical patent/JP7357002B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020557924A 2018-04-18 2019-04-01 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド Active JP7357002B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023159941A JP2023174697A (ja) 2018-04-18 2023-09-25 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862659693P 2018-04-18 2018-04-18
US62/659,693 2018-04-18
US201962820558P 2019-03-19 2019-03-19
US62/820,558 2019-03-19
PCT/US2019/025253 WO2019204021A1 (en) 2018-04-18 2019-04-01 Pcsk9 targeting oligonucleotides for treating hypercholesterolemia and related conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023159941A Division JP2023174697A (ja) 2018-04-18 2023-09-25 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド

Publications (4)

Publication Number Publication Date
JP2021521796A JP2021521796A (ja) 2021-08-30
JPWO2019204021A5 JPWO2019204021A5 (https=) 2022-04-07
JP2021521796A5 true JP2021521796A5 (https=) 2022-04-07
JP7357002B2 JP7357002B2 (ja) 2023-10-05

Family

ID=68239855

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020557924A Active JP7357002B2 (ja) 2018-04-18 2019-04-01 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド
JP2023159941A Withdrawn JP2023174697A (ja) 2018-04-18 2023-09-25 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023159941A Withdrawn JP2023174697A (ja) 2018-04-18 2023-09-25 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド

Country Status (10)

Country Link
US (2) US11566248B2 (https=)
EP (1) EP3765611A4 (https=)
JP (2) JP7357002B2 (https=)
KR (1) KR102749200B1 (https=)
CN (1) CN112368381A (https=)
AU (1) AU2019255460A1 (https=)
CA (1) CA3097585A1 (https=)
IL (1) IL278086A (https=)
MX (1) MX2020011006A (https=)
WO (1) WO2019204021A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
US11566248B2 (en) 2018-04-18 2023-01-31 Dicerna Pharmaceuticals, Inc. PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions
WO2020226960A1 (en) 2019-05-03 2020-11-12 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
US20220290156A1 (en) * 2019-08-27 2022-09-15 Sanofi Compositions and methods for inhibiting pcsk9
WO2022089486A1 (zh) * 2020-10-28 2022-05-05 江苏柯菲平医药股份有限公司 抑制PCSK9基因表达的siRNA及其修饰物与应用
CN114634929A (zh) * 2020-12-16 2022-06-17 施能康生物科技有限公司 靶向前蛋白转化酶枯草杆菌转化酶的核酸及其用途
WO2023017004A1 (en) * 2021-08-09 2023-02-16 Cargene Therapeutics Pte. Ltd. Inhibitory nucleic acids for pcsk9
CN120272480A (zh) * 2021-09-30 2025-07-08 北京安龙生物医药有限公司 用于治疗与pcsk9相关疾病的靶向寡核苷酸
CN118786216A (zh) * 2022-01-13 2024-10-15 石药集团中奇制药技术（石家庄）有限公司 一种抑制PCSK9基因表达的RNAi剂及其应用
JP2025520520A (ja) * 2022-06-14 2025-07-03 大睿生物 ＰＣＳＫ９遺伝子活性を調節するｓｉＲＮＡ分子
CN118086311B (zh) * 2023-05-25 2024-08-09 苏州时安生物技术有限公司 抑制PCSK9基因表达的siRNA、其缀合物和药物组合物及用途
CN121866332A (zh) * 2023-06-21 2026-04-14 美国圣因生物股份有限公司 靶向前蛋白转化酶枯草杆菌蛋白酶kexin 9（pcsk9）的双链rna及其使用方法
CN119040325B (zh) * 2023-09-18 2025-07-18 广州必贝特医药股份有限公司 用于同时抑制两个靶基因表达的siRNA、药物及其应用
CN117106781B (zh) * 2023-10-16 2024-03-22 深圳市茵冠生物科技有限公司 修饰的核酸及其产品和应用
WO2025096355A1 (en) * 2023-10-29 2025-05-08 Corsera Llc Improved sirna for silencing expression of pcsk9 and uses thereof
CN117210468B (zh) * 2023-11-06 2024-02-20 北京悦康科创医药科技股份有限公司 靶向调控PCSK9基因表达的siRNA及其应用
CN117384907B (zh) * 2023-12-11 2024-03-29 上海鼎新基因科技有限公司 抑制PCSK9表达的siRNA分子及其应用
CN118109463B (zh) * 2024-01-31 2025-02-21 北京悦康科创医药科技股份有限公司 靶向PCSK9基因的siRNA及其应用
WO2026026812A1 (zh) * 2024-07-29 2026-02-05 成都先衍生物技术有限公司 一种具有双靶点基因抑制作用的核酸缀合物及其应用
WO2026026811A1 (zh) * 2024-07-29 2026-02-05 成都先衍生物技术有限公司 一种具有双靶点基因抑制作用的核酸缀合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874149T3 (es) * 2006-05-11 2021-11-04 Alnylam Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión del gen PCSK9
AU2007275365A1 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
JP2010510807A (ja) * 2006-11-27 2010-04-08 アイシス ファーマシューティカルズ， インコーポレーテッド 高コレステロール血症を治療するための方法
WO2008109369A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
WO2009114475A2 (en) * 2008-03-09 2009-09-17 Intradigm Corporation Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
NZ597504A (en) * 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
WO2012058693A2 (en) 2010-10-29 2012-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of pcsk9 genes
JP7105065B2 (ja) * 2014-12-15 2022-07-22 ダイセルナ ファーマシューティカルズ， インコーポレイテッド リガンド修飾二本鎖核酸
US11566248B2 (en) * 2018-04-18 2023-01-31 Dicerna Pharmaceuticals, Inc. PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions

Similar Documents

Publication Publication Date Title
JP2021521796A5 (https=)
JPWO2019204021A5 (https=)
JP2021511042A5 (https=)
JP2019214587A5 (https=)
JP2020529197A5 (https=)
TWI880645B (zh) 抑制lpa之基因表現之組合物及方法
JP2021006029A5 (https=)
JP2023103244A5 (https=)
JP2021533804A5 (https=)
JP2020188756A5 (https=)
JP2020500929A5 (https=)
JP2020534268A (ja) アンジオポエチン様３（ＡＮＧＰＴＬ３）の発現を阻害するためのＲＮＡｉ剤および組成物、ならびに使用方法
JP2017532038A5 (https=)
JP2021533762A5 (https=)
JP2018519797A5 (https=)
JP2013535212A5 (https=)
JP2009514877A5 (https=)
JP2018512155A5 (https=)
IL295086A (en) Compositions and methods for inhibiting expression of hmgb1
JPWO2021119034A5 (https=)
JP2021517826A5 (https=)
CA3159501A1 (en) Methods of synthesizing rna molecules
JPWO2020041769A5 (https=)
JPWO2023283531A5 (https=)
US6087484A (en) Enhancement of ribozyme catalytic activity by A 2'-O-substituted facilitator oligonucleotide